Literature DB >> 10101147

Monospecific antipeptide antibody to cytochrome P-450 2B6.

D M Stresser1, D Kupfer.   

Abstract

To study cytochrome P-450 (CYP) 2B6 contribution to methoxychlor metabolism within human liver microsomes and to initiate an investigation of CYP2B6 protein expression, we developed a polyclonal antibody targeted to a 20-residue peptide within that protein. The antibody was found to be highly sensitive and monospecific for CYP2B6 on immunoblots. Although many immunological studies have described the absence or low expression of CYP2B6 in human livers, in the present investigation, we have found this not to be the case. We immunoquantified CYP2B6 apoprotein expression in a panel of 28 livers and found concentrations ranging from 2 to 82 pmol/mg protein, with a mean value of 25 pmol/mg protein. Five livers ( approximately 18%) displayed relatively high levels of CYP2B6 (>40 pmol/mg protein). There were no sex-related differences, although the highest level was observed in a 1-week postpartum donor given several medications. A marked diminution in variability was found in individuals aged 56 or older (n = 12), but there were no age-related trends in mean CYP2B6 content. We suggest that CYP2B6 represents a significant portion of total CYP in human liver. The exquisite sensitivity of this antibody (fmol quantities are detected easily on immunoblots) may explain our detection of CYP2B6 in 100% of livers versus its detection in a limited number of livers by certain other investigators. The antibody also was found to immunoinhibit CYP2B6-catalyzed N-demethylation of (S)-mephenytoin in human liver microsomes by 68 to 79%. The utility of this antibody for determining human liver microsomal CYP2B6 contribution to the ortho-hydroxylation of methoxychlor was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10101147

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion.

Authors:  Robert J Foxenberg; Corie A Ellison; James B Knaak; Changxing Ma; James R Olson
Journal:  Toxicology       Date:  2011-04-13       Impact factor: 4.221

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

3.  Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation.

Authors:  Haishan Li; Stephen S Ferguson; Hongbing Wang
Journal:  Mol Pharmacol       Date:  2010-07-12       Impact factor: 4.436

4.  Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.

Authors:  Zeruesenay Desta; Ingrid F Metzger; Nancy Thong; Jessica B L Lu; John T Callaghan; Todd C Skaar; David A Flockhart; Raymond E Galinsky
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

5.  The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.

Authors:  Katarina Ilic; Roy L Hawke; Ranjit K Thirumaran; Erin G Schuetz; J Heyward Hull; Angela D M Kashuba; Paul W Stewart; Celeste M Lindley; Mei-Ling Chen
Journal:  Drug Metab Dispos       Date:  2012-12-13       Impact factor: 3.922

6.  Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.

Authors:  Chitra Sridar; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-08-30       Impact factor: 3.922

7.  Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices.

Authors:  Hélène Martin; Jean-Pierre Sarsat; Isabelle de Waziers; Chantal Housset; Pierre Balladur; Philippe Beaune; Véronique Albaladejo; Carole Lerche-Langrand
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

8.  Synthetic antibody libraries focused towards peptide ligands.

Authors:  Christian W Cobaugh; Juan C Almagro; Mark Pogson; Brent Iverson; George Georgiou
Journal:  J Mol Biol       Date:  2008-03-04       Impact factor: 5.469

Review 9.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

Authors:  Hongbing Wang; Leslie M Tompkins
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

10.  Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro.

Authors:  Einosuke Tanaka; Yui Takano; Shinichi Inomata; Hidenori Toyooka; Katsuya Honda
Journal:  Eur J Clin Pharmacol       Date:  2004-09-04       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.